Blood Test Detects Lingering Lung Damage After COVID-19: UK Study's Biomarker Breakthrough

🔬 Uncovering Hidden Lung Damage Through Simple Blood Tests

A groundbreaking study from leading UK researchers has revealed that a straightforward blood test can detect lingering lung damage in patients hospitalized for COVID-19, even months after their initial infection. Conducted as part of the extensive PHOSP-COVID initiative, this research analyzed blood samples from nearly 1,000 participants and pinpointed specific biomarkers signaling ongoing injury to the delicate lining of the lungs. These findings, published in early 2026, offer hope for earlier identification and management of post-COVID respiratory issues, which continue to affect a significant number of survivors.

The study, involving experts from the University of Leicester, Imperial College London, and University College London, focused on patients who had been hospitalized with acute COVID-19. At around five months post-discharge, researchers measured levels of four key biomarkers associated with epithelial lung injury: matrix metalloproteinase-7 (MMP-7), Krebs von den Lungen-6 (KL-6), surfactant protein-D (SP-D), and surfactant protein-A (SP-A). Elevated concentrations of these proteins in the blood were strongly linked to residual lung abnormalities (RLA) visible on computed tomography (CT) scans, such as ground-glass opacities and reticular patterns indicative of inflammation or early fibrosis.

For those unfamiliar, epithelial cells form the thin barrier inside the lungs that protects against inhaled particles, produces protective mucus, and triggers immune responses. Damage here disrupts normal lung function, leading to symptoms like persistent shortness of breath (dyspnoea) and reduced ability to exercise. In the study, about 11% of participants were classified as at-risk for RLA based on impaired gas transfer (measured by diffusing capacity for carbon monoxide or DLCO below 80% predicted) or abnormal chest X-rays. Among those who underwent CT scans, 76.6% showed significant RLA covering at least 10% of their lung tissue.

📊 Key Biomarkers and What They Reveal

The biomarkers serve as molecular messengers of lung cell distress. Here's a breakdown of each, based on the study's detailed assays:

• MMP-7 (Matrix Metalloproteinase-7): This enzyme helps remodel the extracellular matrix, the scaffold supporting lung tissue. Levels were markedly higher in patients with RLA—0.85 standard deviations above those without (p < 0.001)—suggesting active fibrotic processes that could lead to scarring.
• KL-6 (Krebs von den Lungen-6): A mucin-like glycoprotein released from damaged alveolar type II cells, which produce surfactant to keep air sacs open. Elevated by 0.67 SD in RLA cases (p = 0.001), it correlated strongly with the extent of reticulation on scans.
• SP-D (Surfactant Protein-D) and SP-A (Surfactant Protein-A): These proteins stabilize lung surfactant and aid immune defense. While less discriminatory overall, they associated with reticular changes (SP-D increased lung involvement by 3.22% per unit rise, p = 0.002), pointing to club cell and alveolar damage.

Statistical models showed these markers improved prediction accuracy for RLA. Admission characteristics alone yielded an area under the receiver operating characteristic curve (AUROC) of 0.63 for at-risk status; adding MMP-7 and KL-6 boosted it to 0.70 (p = 0.008). This means a blood test could soon help clinicians stratify patients, avoiding unnecessary scans while flagging those needing closer watch.

🫁 Understanding Residual Lung Abnormalities (RLA)

RLA refers to persistent changes on lung imaging post-infection, including hazy ground-glass opacities (GGO) from inflammation or fluid, and reticulation—net-like fibrosis patterns. Unlike acute pneumonia, these linger, impairing gas exchange and contributing to fatigue and breathlessness. Meta-analyses indicate 29% of survivors show fibrotic patterns and 50% inflammatory ones at three months, with dyspnoea in 37% and restrictive lung patterns in 17%.

In this cohort, RLA extent correlated dose-dependently with biomarker levels. For every unit increase in MMP-7 z-score, reticulation coverage rose by 3.58% (95% CI 2.04-5.13, p < 0.001). Spatial transcriptomics from COVID-19 lung tissue confirmed upregulated genes for these proteins in injured epithelial cells, validated by immunohistochemistry showing MMP-7 in damaged areas.

Such abnormalities may stem from persistent epithelial injury triggering pro-fibrotic cascades, akin to idiopathic pulmonary fibrosis (IPF). While many resolve, some progress, underscoring the need for monitoring. Patients with severe initial illness, like those on invasive mechanical ventilation (31.5% in the CT group), were overrepresented, but associations held after adjustments for age, sex, and ventilation.

🎓 The PHOSP-COVID Study: A Landmark in Recovery Research

PHOSP-COVID, led by the University of Leicester and University Hospitals of Leicester NHS Trust, is a national consortium tracking over 1,000 hospitalized patients' recovery. Launched to address why fewer than 30% fully recover by one year, it collects clinical data, imaging, and biosamples. Risk factors include older age, obesity, comorbidities, and prolonged admission.

This UK Interstitial Lung Disease (ILD) Post-COVID substudy leveraged its tiered design: 957 provided plasma at median 170 days post-discharge. Blinded CT scoring ensured objectivity. Contributors hail from premier institutions, exemplifying collaborative higher education efforts in medical science. Such interdisciplinary work drives innovations, opening doors for careers in respiratory research—consider exploring research jobs at leading universities.

The study's rigor, with log-transformed assays on a high-sensitivity analyzer and multivariable modeling, sets a gold standard. Limitations include no healthy controls (elevated markers even in low-risk suggest subclinical injury) and variable CT timing, but findings robustly link blood signals to parenchymal changes.

💡 Clinical Implications and Patient Advice

For patients with unexplained breathlessness post-COVID, these results herald a non-invasive screening tool. Dr. Rachael Evans notes, “The biomarkers tell us there is damage to this lining, contributing to ongoing symptoms and restrictive lung function.” Early detection could prompt interventions like pulmonary rehabilitation, oxygen therapy, or antifibrotic drugs tested in IPF.

Professor Gisli Jenkins highlights the potential to “identify people at increased risk of chronic lung disease.” Dr. Iain Stewart emphasizes reliable markers' importance given lifelong consequences. If experiencing dyspnoea, reduced exercise tolerance, or fatigue:

• Consult your GP for lung function tests like spirometry or DLCO.
• Discuss symptom history and request imaging if warranted.
• Adopt lifestyle measures: smoking cessation, weight management, and graded exercise.
• Monitor for progression, as 11% remain at-risk.

Read the full study in eBioMedicine for deeper insights.

🔮 Future Directions in Post-COVID Lung Research

Building on this, longitudinal tracking (e.g., repeat CTs in 15 patients showed persistent reticulation tied to SP-D) could clarify resolution rates. Validating in diverse populations and against healthy norms is next. Trials targeting epithelial repair or fibrosis (e.g., via MMP inhibitors) may emerge.

PHOSP-COVID's five-year follow-up promises more data. Gene expression analyses reinforce epithelial origins, guiding therapies. Visit the PHOSP-COVID website for updates. University-led research like this fuels advancements—academics drive solutions through professor jobs and grants.

Broader long COVID context: while vaccines reduced severe cases, hospitalized survivors face multi-organ risks. Balanced views stress personalized care over alarmism.

Photo by Jyoti Singh on Unsplash

📝 Wrapping Up: Hope on the Horizon

This UK study transforms post-COVID care, turning invisible lung damage into actionable data via blood tests. By spotlighting biomarkers like MMP-7 and KL-6, it empowers clinicians to intervene early, improving quality of life. Grateful to participants enabling such progress, as Prof. Louise Wain affirms.

For those navigating recovery or pursuing research careers, resources abound. Share experiences on Rate My Professor, seek higher ed jobs in biomedicine, or explore academic CV tips. Stay informed and proactive—your health and career matter.

Check University of Leicester's press release for expert quotes.